Benchmarks for designing two-stage studies using modified mini-mental state examinations

Experience from the Women's Health Initiative Memory Study

Mark A. Espeland, Stephen R. Rapp, Julia Robertson, Iris Granek, Carol Murphy, Marilyn Albert, Tamsen Bassford

Research output: Contribution to journalArticle

Abstract

Background: The most efficient approach for studies examining the incidence of dementia involves a brief screening instrument to identify participants for more extensive testing to identify cognitive impairment. The modified mini-mental state examination (3MS) is commonly used as this initial screen in such two-stage designs, however its properties for this role require further study. Purpose: We use data from the Women's Health Initiative Memory Study to contrast design options in two-stage designs. Methods: This trial enrolled 7251 participants with nine or more years of education who were aged 65-79 and followed an average of four to five years. Logistic regression was used to examine the case yields at varying two-stage 3MS cutpoints. The efficiency of using different examination schedules and restricting enrollment to higher risk women was examined. Results: Probable dementia is associated with marked decline in 3MS scores. The percentages of women classified with probable dementia ranged from 7.95% (3MS 85-88) to 50.0% (3MS <70). The numbers [95% confidence interval] of enrolled women necessary to detect one case of probable dementia (four-year follow-up) for baseline 3MS scores of 100, 95, 90 and 85 were estimated as 1477 [389, 5618], 253 [134, 481], 53 [34, 85], and 14 [9, 23], respectively. Compared to annual testing, administration every two years increased the number of required enrollees by 11%, but decreased the number of test administrations by 46%. Limitations: Our findings are influenced by the characteristics of our study group, its rates of retention, and the study protocol, and may not fully generalize to other settings. Conclusions: The 3MS can serve as an efficient basis for two-stage study designs and a cutpoint of ≤88 is reasonable for populations with similar characteristics. Studies may improve efficiency by using the 3MS during screening to eliminate women with low risk for dementia and by conducting testing every two years.

Original languageEnglish (US)
Pages (from-to)99-106
Number of pages8
JournalClinical Trials
Volume3
Issue number2
DOIs
StatePublished - 2006

Fingerprint

Benchmarking
Women's Health
Dementia
Efficiency
Appointments and Schedules
Cohort Studies
Logistic Models
Confidence Intervals
Education
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Benchmarks for designing two-stage studies using modified mini-mental state examinations : Experience from the Women's Health Initiative Memory Study. / Espeland, Mark A.; Rapp, Stephen R.; Robertson, Julia; Granek, Iris; Murphy, Carol; Albert, Marilyn; Bassford, Tamsen.

In: Clinical Trials, Vol. 3, No. 2, 2006, p. 99-106.

Research output: Contribution to journalArticle

Espeland, Mark A. ; Rapp, Stephen R. ; Robertson, Julia ; Granek, Iris ; Murphy, Carol ; Albert, Marilyn ; Bassford, Tamsen. / Benchmarks for designing two-stage studies using modified mini-mental state examinations : Experience from the Women's Health Initiative Memory Study. In: Clinical Trials. 2006 ; Vol. 3, No. 2. pp. 99-106.
@article{0619d450eaf34f369eb67aa611d94fea,
title = "Benchmarks for designing two-stage studies using modified mini-mental state examinations: Experience from the Women's Health Initiative Memory Study",
abstract = "Background: The most efficient approach for studies examining the incidence of dementia involves a brief screening instrument to identify participants for more extensive testing to identify cognitive impairment. The modified mini-mental state examination (3MS) is commonly used as this initial screen in such two-stage designs, however its properties for this role require further study. Purpose: We use data from the Women's Health Initiative Memory Study to contrast design options in two-stage designs. Methods: This trial enrolled 7251 participants with nine or more years of education who were aged 65-79 and followed an average of four to five years. Logistic regression was used to examine the case yields at varying two-stage 3MS cutpoints. The efficiency of using different examination schedules and restricting enrollment to higher risk women was examined. Results: Probable dementia is associated with marked decline in 3MS scores. The percentages of women classified with probable dementia ranged from 7.95{\%} (3MS 85-88) to 50.0{\%} (3MS <70). The numbers [95{\%} confidence interval] of enrolled women necessary to detect one case of probable dementia (four-year follow-up) for baseline 3MS scores of 100, 95, 90 and 85 were estimated as 1477 [389, 5618], 253 [134, 481], 53 [34, 85], and 14 [9, 23], respectively. Compared to annual testing, administration every two years increased the number of required enrollees by 11{\%}, but decreased the number of test administrations by 46{\%}. Limitations: Our findings are influenced by the characteristics of our study group, its rates of retention, and the study protocol, and may not fully generalize to other settings. Conclusions: The 3MS can serve as an efficient basis for two-stage study designs and a cutpoint of ≤88 is reasonable for populations with similar characteristics. Studies may improve efficiency by using the 3MS during screening to eliminate women with low risk for dementia and by conducting testing every two years.",
author = "Espeland, {Mark A.} and Rapp, {Stephen R.} and Julia Robertson and Iris Granek and Carol Murphy and Marilyn Albert and Tamsen Bassford",
year = "2006",
doi = "10.1191/1740774506cn140oa",
language = "English (US)",
volume = "3",
pages = "99--106",
journal = "Clinical Trials",
issn = "1740-7745",
publisher = "SAGE Publications Ltd",
number = "2",

}

TY - JOUR

T1 - Benchmarks for designing two-stage studies using modified mini-mental state examinations

T2 - Experience from the Women's Health Initiative Memory Study

AU - Espeland, Mark A.

AU - Rapp, Stephen R.

AU - Robertson, Julia

AU - Granek, Iris

AU - Murphy, Carol

AU - Albert, Marilyn

AU - Bassford, Tamsen

PY - 2006

Y1 - 2006

N2 - Background: The most efficient approach for studies examining the incidence of dementia involves a brief screening instrument to identify participants for more extensive testing to identify cognitive impairment. The modified mini-mental state examination (3MS) is commonly used as this initial screen in such two-stage designs, however its properties for this role require further study. Purpose: We use data from the Women's Health Initiative Memory Study to contrast design options in two-stage designs. Methods: This trial enrolled 7251 participants with nine or more years of education who were aged 65-79 and followed an average of four to five years. Logistic regression was used to examine the case yields at varying two-stage 3MS cutpoints. The efficiency of using different examination schedules and restricting enrollment to higher risk women was examined. Results: Probable dementia is associated with marked decline in 3MS scores. The percentages of women classified with probable dementia ranged from 7.95% (3MS 85-88) to 50.0% (3MS <70). The numbers [95% confidence interval] of enrolled women necessary to detect one case of probable dementia (four-year follow-up) for baseline 3MS scores of 100, 95, 90 and 85 were estimated as 1477 [389, 5618], 253 [134, 481], 53 [34, 85], and 14 [9, 23], respectively. Compared to annual testing, administration every two years increased the number of required enrollees by 11%, but decreased the number of test administrations by 46%. Limitations: Our findings are influenced by the characteristics of our study group, its rates of retention, and the study protocol, and may not fully generalize to other settings. Conclusions: The 3MS can serve as an efficient basis for two-stage study designs and a cutpoint of ≤88 is reasonable for populations with similar characteristics. Studies may improve efficiency by using the 3MS during screening to eliminate women with low risk for dementia and by conducting testing every two years.

AB - Background: The most efficient approach for studies examining the incidence of dementia involves a brief screening instrument to identify participants for more extensive testing to identify cognitive impairment. The modified mini-mental state examination (3MS) is commonly used as this initial screen in such two-stage designs, however its properties for this role require further study. Purpose: We use data from the Women's Health Initiative Memory Study to contrast design options in two-stage designs. Methods: This trial enrolled 7251 participants with nine or more years of education who were aged 65-79 and followed an average of four to five years. Logistic regression was used to examine the case yields at varying two-stage 3MS cutpoints. The efficiency of using different examination schedules and restricting enrollment to higher risk women was examined. Results: Probable dementia is associated with marked decline in 3MS scores. The percentages of women classified with probable dementia ranged from 7.95% (3MS 85-88) to 50.0% (3MS <70). The numbers [95% confidence interval] of enrolled women necessary to detect one case of probable dementia (four-year follow-up) for baseline 3MS scores of 100, 95, 90 and 85 were estimated as 1477 [389, 5618], 253 [134, 481], 53 [34, 85], and 14 [9, 23], respectively. Compared to annual testing, administration every two years increased the number of required enrollees by 11%, but decreased the number of test administrations by 46%. Limitations: Our findings are influenced by the characteristics of our study group, its rates of retention, and the study protocol, and may not fully generalize to other settings. Conclusions: The 3MS can serve as an efficient basis for two-stage study designs and a cutpoint of ≤88 is reasonable for populations with similar characteristics. Studies may improve efficiency by using the 3MS during screening to eliminate women with low risk for dementia and by conducting testing every two years.

UR - http://www.scopus.com/inward/record.url?scp=33744819480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744819480&partnerID=8YFLogxK

U2 - 10.1191/1740774506cn140oa

DO - 10.1191/1740774506cn140oa

M3 - Article

VL - 3

SP - 99

EP - 106

JO - Clinical Trials

JF - Clinical Trials

SN - 1740-7745

IS - 2

ER -